Oxford, UK (03 October 2012) – BD (Becton, Dickinson and Company), a leading global medical technology company, announces the launch of the new BD Vacutainer® Eclipse™ Signal™ Blood Collection Needle in Europe. The safety-engineered design with single-handed activation, integrated holder and a new flashback chamber offers healthcare workers immediate confirmation of venous access, whilst also reducing the potential for sharps injuries.
Blood collection is one of the most hazardous tasks healthcare workers perform. A European study[i] revealed that it is the procedure with the highest risk of needlestick injury compared to other clinical procedures. A single needlestick injury can expose a healthcare worker to one or more of 30 potentially dangerous blood-borne pathogens, including Hepatitis B, Hepatitis C and HIV [ii].
Luis Fernandez-Inglesias, Vice President, BD Diagnostics, Preanalytical Systems Europe, says: “BD is committed to raising awareness of the risks faced by healthcare workers and educating and informing healthcare facilities on the precautions they can adopt, as well as developing safety-engineered devices for improving healthcare worker safety. The new BD Vacutainer® Eclipse™ Signal™ Blood Collection Needle represents a new level of confidence in safety-engineered devices for venous blood collection, designed specifically with healthcare workers’ safety in mind and ease of use.”
The BD Vacutainer® Eclipse™ Signal™ Blood Collection Needle allows immediate confirmation of venous access, which is indicated by the presence of blood in the flashback chamber, providing confidence during venepuncture. Other key ergonomic features which make venous blood collection simple and more comfortable, are the new anti-slip ridges and thumb pad for easy, single-handed activation of the safety shield. The blood droplet reduction system is designed to reduce blood droplet formation when the needle is removed from the vein, and the needle bevel and safety shield are aligned for easy identification of the needle position for blood collection. Full integration of the holder and needle reduces the risk of user-end sharps injuries and improves efficiency by reducing the number of steps in the blood collection process, with no compromise to patient care.
Mr Kor Kooi, PreAnalytical Manager at UMCG Hospital Groningen, one of the biggest University Hospitals in the Netherlands and the first site in Europe to order the BD Vacutainer® Eclipse™ Signal™, explains: “At Groningen, this new blood collection needle will provide an extra tool to use when carrying out these very important procedures. The flashback chamber makes it much easier to determine if blood collection has been successful, and this invaluable feature also reduces the potential for patient discomfort.”
It is estimated that one million sharps injuries occur in the European Union each year[iii], with more than 100,000 each year in the UK alone[iv]. The EU Directive on the prevention of sharps injuries in the hospital and healthcare sector[v] must be transposed into national law of all EU member states by 11 May 2013, placing an obligation on healthcare organisations “to achieve the safest possible working environment by preventing injuries to workers caused by all medical sharps”[vi].
To find out more about the new blood collection system, healthcare worker safety and how to prepare for the new Directive, please visit BD’s safety website at www.bd.com/europe/safety
About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people’s health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com
